Overview

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

Status:
Terminated
Trial end date:
2018-02-16
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of pimavanserin compared with placebo in treatment of agitation and aggression after 12 weeks of treatment
Phase:
Phase 2
Details
Lead Sponsor:
ACADIA Pharmaceuticals Inc.
Treatments:
Pimavanserin